BCG-Vaccinated Children with Contact to Tuberculosis Patients Show Delayed Conversion of Mycobacterium tuberculosis-Specific IFN-γ Release

Mycobacterium (M.) bovis BCG vaccination is recommended for healthy babies after birth in several countries with a high prevalence of tuberculosis, including Ghana. Previous studies showed that BCG vaccination prevents individuals from developing severe clinical manifestations of tuberculosis, but BCG vaccination effects on the induction of IFN-γ after M. tuberculosis infection have hardly been investigated. Here, we performed IFN-γ-based T-cell assays (i.e., IFN-γ Release Assay, IGRA; T-cell activation and maturation marker assay, TAM-TB) in children who had contact with index tuberculosis patients (contacts). These contacts were classified as either being BCG vaccinated at birth (n = 77) or non-BCG-vaccinated (n = 17) and were followed up at three timepoints for a period of one year to determine immune conversion after M. tuberculosis exposure and potential infection. At baseline and month 3, BCG-vaccinated contacts had significantly lower IFN-γ levels after stimulation with M. tuberculosis-specific proteins as compared to non-BCG-vaccinated contacts. This resulted in decreased proportions of positive IGRA results (BCG-vaccinated: 60% at baseline, 57% at month 3; non-BCG-vaccinated: 77% and 88%, respectively) at month 3. However, until month 12, immune conversion in BCG-vaccinated contacts led to balanced proportions in IGRA responders and IFN-γ expression between the study groups. TAM-TB assay analyses confirmed higher proportions of IFN-γ-positive T-cells in non-BCG-vaccinated contacts. Low proportions of CD38-positive M. tuberculosis-specific T-cells were only detected in non-BCG-vaccinated contacts at baseline. These results suggest that BCG vaccination causes delayed immune conversion as well as differences in the phenotype of M. tuberculosis-specific T-cells in BCG-vaccinated contacts of tuberculosis patients. These differences are immune biomarker candidates for protection against the development of severe clinical tuberculosis manifestations.

[1]  M. Netea,et al.  Trained immunity: implications for vaccination. , 2022, Current opinion in immunology.

[2]  M. Jacobsen,et al.  Interleukin-6 and Mycobacterium tuberculosis dormancy antigens improve diagnosis of tuberculosis. , 2020, The Journal of infection.

[3]  G. Alter,et al.  An observational study identifying highly tuberculosis-exposed, HIV-1-positive but persistently TB, tuberculin and IGRA negative persons with M. tuberculosis specific antibodies in Cape Town, South Africa , 2020, EBioMedicine.

[4]  J. Ferluga,et al.  Natural and trained innate immunity against Mycobacterium tuberculosis. , 2020, Immunobiology.

[5]  M. Netea,et al.  Early Clearance of Mycobacterium tuberculosis: The INFECT Case Contact Cohort Study in Indonesia. , 2019, The Journal of infectious diseases.

[6]  A. Lalvani,et al.  Understanding How BCG Vaccine Protects Against Mycobacterium tuberculosis Infection: Lessons From Household Contact Studies. , 2019, The Journal of infectious diseases.

[7]  M. Jacobsen,et al.  Two-Hit in vitro T-Cell Stimulation Detects Mycobacterium tuberculosis Infection in QuantiFERON Negative Tuberculosis Patients and Healthy Contacts From Ghana , 2019, Front. Immunol..

[8]  M. Hoelscher,et al.  Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy , 2018, Front. Immunol..

[9]  S. Fortune,et al.  Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection , 2018, Nature Reviews Immunology.

[10]  World Health Organization.  BCG vaccine: WHO position paper, February 2018 - Recommendations. , 2018, Vaccine.

[11]  Irah L. King,et al.  BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis , 2018, Cell.

[12]  Helen E Jenkins,et al.  The global burden of tuberculosis mortality in children: a mathematical modelling study , 2017, The Lancet. Global health.

[13]  O. Pryds,et al.  The association between Bacillus Calmette-Guérin vaccination (1331 SSI) skin reaction and subsequent scar development in infants , 2017, BMC Infectious Diseases.

[14]  M. Jacobsen,et al.  Alternative Quantiferon cytokines for diagnosis of children with active tuberculosis and HIV co-infection in Ghana , 2017, Medical Microbiology and Immunology.

[15]  M. Jacobsen,et al.  Multiple cytokines for the detection of Mycobacterium tuberculosis infection in children with tuberculosis. , 2017, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[16]  S. Ray,et al.  Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. , 2015, The Journal of clinical investigation.

[17]  Michael Hoelscher,et al.  Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study. , 2014, The Lancet. Infectious diseases.

[18]  J. Sterne,et al.  Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Alimuddin Zumla,et al.  Immunological biomarkers of tuberculosis , 2011, Nature Reviews Immunology.

[20]  S. Sridhar,et al.  BCG vaccination: 90 years on and still so much to learn … , 2010, Thorax.

[21]  C. Barry,et al.  Age and the epidemiology and pathogenesis of tuberculosis , 2010, The Lancet.

[22]  S. Kaufmann,et al.  Identification of T-Cell Antigens Specific for Latent Mycobacterium Tuberculosis Infection , 2009, PloS one.

[23]  J. Deeks,et al.  Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak , 2003, The Lancet.